BioClec
Pioneering microglial therapies for Alzheimer's disease
Milan, Italy · Founded 2025
- Headquarters
- Milan
- Employees
- 1–10
- Founded
- 2025
- Business Model
- B2B
- Website
- bioclec.com
- Last Round
- SeedMar 2025
- Rounds
- 1
About
BioClec is a Milan, Italy-based biotechnology company launched in March 2025, focused on developing pioneering therapies for Alzheimer's disease. Emerging from Sofinnova Partners' 165M euro Biovelocita II accelerator program, BioClec targets microglia — the brain's critical immune cell population — to develop disease-modifying interventions via a novel microglial pathway. The company was co-founded by Dr. Marco Colonna, a global expert in neuroimmunology and Professor of Pathology & Immunology at Washington University School of Medicine, and is led by CEO Gabriella Camboni.
Summary
BioClec is a Biotech company based in Milan, Italy, founded in 2025. Its most recent funding was a Seed round in Mar 2025. Investors include Sofinnova Partners.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2025
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...